Every reporter: Wang Yandan Every editor: He Jianling
Image source: Photo Network_500600373
The interaction and relationship between brokerage research and listed companies has always been the focus of the market. Recently, Orient Bio, a big bull stock, has encountered a little bit of “trouble”: due to too much increase and too high market heat, it had to issue a stock price change announcement.
In the announcement, Orient Biotech specifically mentioned: the company is concerned that the research department of CITIC Securities released “the United States launches a new crown rapid detection plan, breeds a new blue ocean for antigen testing, and raises the target price” on January 13, 2022. A profit forecast has been made on the performance. In order to avoid misleading investors and safeguard the legitimate rights and interests of the company, the company makes the following statement: the report is only the opinion of the research department of CITIC Securities and does not represent the company’s position.
daily economic newsReturn to Sohu, see more
Editor:
Statement: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.
.